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The effect of bile acids administration to an experimental mice model of Protoporphyria produced by griseofulvin (Gris) was
investigated. The aim was to assess whether porphyrin excretion could be accelerated by bile acids treatment in an attempt to
diminish liver damage induced by Gris. Liver damage markers, heme metabolism, and oxidative stress parameters were analyzed
in mice treated with Gris and deoxycholic (DXA), dehydrocholic (DHA), chenodeoxycholic, or ursodeoxycholic (URSO). The
administration of Gris alone increased the activities of glutathione reductase (GRed), superoxide dismutase (SOD), alkaline
phosphatase (AP), gamma glutamyl transpeptidase (GGT), and glutathione-S-transferase (GST), as well as total porphyrins,
glutathione (GSH), and cytochrome P450 (CYP) levels in liver. Among the bile acids studied, DXA and DHA increased PROTO IX
excretion, DXA also abolished the action of Gris, reducing lipid peroxidation and hepatic GSH and CYP levels, and the activities of
GGT, AP, SOD, and GST returned to control values. However, porphyrin accumulation was not prevented by URSO; instead this
bile acid reduced ALA-S and the antioxidant defense enzymes system activities. In conclusion, we postulate that DXA acid would
be more effective to prevent liver damage induced by Gris.
Dedicated to Swe, our good colleague and very dearest friend
1. Introduction
Erythropoietic protoporphyria (EPP) is a hereditary dis-
ease due to a decreased activity of ferrochelatase (Fech)
(EC.4.99.1.1), the last enzyme of heme pathway catalyzing
the incorporation of ferrous iron (II) into protoporphyrin IX
(PROTO IX) to synthetize heme [1, 2]. EPP patients show
clinical manifestations attributed to the excessive accumula-
tion of PROTO IX, mainly in erythrocytes, liver, and skin. All
symptomatic patients show photosensitivity because of the
presence of PROTO IX in the skin that generates free radicals
after its activation by light [3, 4]. A few EPP patients develop
chronic liver disease [5]. There is a correlation between
liver damage and PROTO IX concentration in erythrocytes
which in some cases is so severe that it could require liver
transplantation [6, 7].
PROTO IX is excreted by the hepatobiliary-fecal route
and canmove to the enterohepatic recirculation.The entrance
of PROTO IX to the liver is not saturated; when its excretion
through the bile fails to remove the excess of PROTO IX
produced by the bone marrow and the liver, this porphyrin
accumulates in hepatocytes [8].
Bile acids have choleretic and digestive actions. In
humans, bile salts are used as a cathartic to promote bile
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flow after biliary surgery and to reverse the formation of
calculi. In EPP patients bile acids have been used to increase
liver porphyrins excretion enhancing cholestasis and in the
established cirrhosis to improve both cholestasis and liver
function [9–11].
The antifungal griseofulvin (Gris) develops in animals a
model of EPP [12] with liver manifestations [13, 14]. Gris is
metabolized through cytochrome P450 (CYP) producing N-
methyl PROTO IX a potent inhibitor of Fech enzyme [15, 16].
When administrating Gris to mice, several morphological
and biochemical hepatic changes were observed, as a result
of a marked inhibition of Fech and the reduction of the heme
regulatory pool that, secondarily, stimulates the enzyme 𝛿-
aminolevulinic acid synthetase (ALA-S). To porphyrin accu-
mulation followed cellular damage, inflammatory and ne-
crotic events [17], resembling human EPP associated with
liver failure. The high concentration of porphyrins, known
generators of reactive oxygen species (ROS), affects hepatic
redox balance and, consequently, the antioxidant defense
enzymes system. In animals treated with Gris, we observed
an increased activity of the enzymes glutathione reductase
(GRed), superoxide dismutase (SOD), and glutathione-S-
transferase (GST) and high levels of reduced glutathione
(GSH) and malondialdehyde (MDA), while the activities of
glutathione peroxidase (GPx) and catalase were reduced [17].
Gris also induces bile flow reduction as a result of liver
damage, leading to the hepatocytes accumulation of toxic
endogenous bile acids such as taurocholic and taurodeoxy-
cholic acid [18].
Themain difference between humanEPP andGris animal
model is that the overproduction of PROTO IX in the latter
begins in the liver instead of the bone marrow [3, 19].
Considering the damage produced by Gris in mice liver,
the aim of this study was to investigate the effect of admin-
istrating deoxycholic (DXA), dehydrocholic (DHA), chen-
odeoxycholic (CHENO), and ursodeoxycholic (URSO) acids
on heme metabolism, antioxidant defense enzymes system,
and CYP levels in Gris treated mice, to assess whether they
were able to accelerate the excretion of porphyrins through
the bilis, in an attempt to diminish liver damage.
2. Materials and Methods
2.1. Animals. Male mice CF1 weighing 15–17 g at the start
of intoxication were used. They were maintained in con-
trolled conditions and allowed free access to food (Purina 3,
Asociacio´n de Cooperativas Argentinas, San Nicola´s, Buenos
Aires, Argentina) and water. A 12/12 h light/dark cycle was
kept. Animals received human care and were treated in
accordance with the guidelines established by the Committee
of the Argentine Association of Specialists in Laboratory
Animals Care (AADEALC).
2.2. Experimental Design. All treatments were performed at
the same time of the day. In each experiment, animals were
separated into 4 groups of 6 mice each and during two
weeks they received the drugs as follows: group I: control
diet (standard diet supplemented with corn oil, 10mL/100 g);
group II: control diet plus Gris (0.5% w/w; 280mg/mice/2
weeks); group III: control diet plus DXA (0.33%; 231mg/
mice/2 weeks) in the drinking water or CHENO (0.01%
w/w; 6mg/mice/2 weeks), DHA (0.33% w/w; 190mg/mice/2
weeks), or URSO (0.2% w/w; 112mg/mice/2 weeks) in food:
group IV: control diet plus Gris (0.5% w/w; 280mg/mice/2
weeks) andDXA (0.33%; 231mg/mice/weeks) in the drinking
water or CHENO (0.01% w/w; 6mg/mice/2 weeks), DHA
(0.33% w/w; 190mg/mice/2 weeks), or URSO (0.2% w/w;
112mg/mice/2 weeks) in food. Animals were starved 16 hours
before sacrifice under ether anaesthesia.
2.3. Tissue Preparation. Blood was obtained by cardiac punc-
ture and plasma was separated by centrifugation. The faeces
of each cage were collected during the 16 hours before
sacrifice. Liver was removed and immediately processed.
Experimental conditions for liver homogenate preparations
were different, depending on the parameter assayed. A
fraction of the liver was immediately homogenized (1 : 3, w/v)
in a solution containing 0.9% NaCl, 0.1mM Tris HCl pH
7.4, and 0.5mM EDTA, for ALA-S activity determination.
The remainder of the organ, previously perfused with sterile
ice cold saline, was removed. A fraction was homogenized
(1 : 3, w/v) in ice cold 0.25M sucrose. After differential
centrifugation of this homogenate, supernatant of 10,000×g
was used for measuring GSH levels and GST activity. An
aliquot of this supernatant was then centrifuged at 105,000×g
for 60min.The supernatant obtained was used formeasuring
SOD activity and the pellet for determining total CYP levels.
Another fraction of the perfused liver was homogenized
(1 : 10, w/v) in 0.05M sodium phosphate buffer, pH 7.4, and
it was used as such for the determination of MDA or it was
centrifuged at 10,000×g for 10min; in this supernatant GRed
activity was measured. The other fraction of the perfused
liver (200–300mg) was used for quantifying PROTO IX
levels. Porphyrins were extracted from liver using themethod
described by De Matteis and Lim [20] and from faeces
according to the method of Lockwood et al. [21].
2.4. Biochemical Assays. ALA-S activity was determined fol-
lowing the method of Marver et al. [22]. Lipid peroxidation
was estimated as MDA levels using the method of Ohkawa
et al. [23]. GSH was quantified according to Rossi et al.
[24]. GST, GRed, and SOD activities were determined by
the methods of Habig et al. [25], Pinto and Bartley [26],
and Paoletti et al. [27], respectively. Total CYP levels were
measured according to Omura and Sato [28] and protein
concentration was measured by the procedure of Lowry
et al. [29]. Plasma activities of AP and GGT were determined
using a kit from Wiener lab. (Rosario, Argentina). PROTO
IXwas quantified fluorometrically (𝜆ex 400 nm, 𝜆em 632 nm).
Enzyme units were defined as the amount of enzyme that
catalyzes the formation of 1 nmol of product under the
standard incubation conditions. One unit of SOD is defined
as the amount of enzyme causing 50% inhibition on the rate of
NADH oxidation measured in the control. Specific activities
were expressed as units/mg protein.
BioMed Research International 3
2.5. Histology and Immunohistochemistry. Livers were re-
moved and fixed in 10% neutral-buffered formalin. Sam-
ples of each hepatic lobule were processed routinely and
embedded in paraffin. At least six microtome sections of 3–
5 𝜇m were stained with Haematoxylin and Eosin. Immuno-
histochemistry for heme oxygenase (HO1) detection was
performed using the streptavidin-biotin-peroxidase complex
system LSAB (DAKO) as previously reported [17].
2.6. Statistical Analysis. All data represent mean values ±
standard deviation of all experiments performed in duplicate.
The differences between groups were determined by the
analysis of the variance (ANOVA) and the significance level
was verified by the Bartlett test. A probability level of 99.9%
or 99.5% was considered as significant difference between
groups.
3. Results
3.1. Histology and Immunohistochemistry. Histological stud-
ies were performed in livers of mice, receiving 0.5% Gris,
alone and with the bile acids during 14 days. In all
cases, similar alterations were observed (Figure 1(a), control:
Figure 1(g)). The liver plates tend to become disrupted and
distorted. There is an activation of sinusoidal lining cells
with prominent Kupffer’s cells. Hepatocellular alterations,
predominantly ballooning or feathery degeneration, small
foci of necrosis of isolated hepatocytes, and acidophilic
bodies, few in numbers, can be seen. The portal changes
are ductular proliferation, periductal edema, and portal
inflammation. The ductular proliferation occurs along the
margins of the portal triad and the inflammatory infiltrate
is predominantly lymphocytic with some mononuclear cells.
Cytoplasmic and canalicular cholestasis with the presence of
bile plug in interlobular ducts can be seen.
The anti-HO1 immunostaining showed positive mark,
mainly in isolated hepatocytes, being abundant in Kupffer’s
cells in liver of Gris or Gris plus bile acid groups (Figures 1(b),
1(c), 1(d), 1(e), and 1(f); control: Figure 1(h)).
3.2. Hepatic DamageMarkers. No significant alterationswere
detected in liver weight/body weight ratio when DHA, DXA,
URSO, or CHENO was administered to control animals.
Gris increased 40% (𝑃 < 0.01) this parameter but this
enhancement was not reversed by any of the acids assayed
(Figure 2(a)).
Gris induced 40% (𝑃 < 0.05) GGT activity (Figure 2(b)).
When DHA, ADX, or URSO was given to control mice,
no significant differences in GGT activity were observed.
However, CHENO increased 130% (𝑃 < 0.01) this enzyme
activity; such enhancement also occurred in animals receiv-
ing CHENO concomitantly with Gris. This induction was
significantly greater than that produced by Gris alone.
Administration of DHA did not modify the 40% augmented
activity due to Gris. In contrast, DXA andURSO significantly
prevented (𝑃 < 0.05) the induction of GGT caused by Gris,
returning to basal levels (Figure 2(b)).
All bile acids assayed prevented the increase of AP activity
(80%, 𝑃 < 0.01) produced by Gris (Figure 2(c)).
3.3. Heme Biosynthesis. ALA-S activity was increased 40%
(𝑃 < 0.01) in animals treated with Gris. All the bile acids
given alone diminished 40% (𝑃 < 0.01) ALA-S, but when
theywere administeredwithGris, no effectwas observedwith
respect to those animals receiving only Gris, except in the
case of URSO which restored ALA-S activity to basal levels
(Figure 3).
The accumulation of PROTO IX in liver increased 50-fold
by the action of Gris alone or Gris plus CHENO or URSO;
however, DHA or DXA administration reduced around 90%
(𝑃 < 0.01) porphyrin enhancement levels induced by Gris,
but without returning to basal levels (Table 1).
Among the bile acids studied, only CHENO increased
fecal PROTO IX excretion (3-fold with respect to control
group). Instead, Gris increased 400% (𝑃 < 0.01) PROTO
IX excretion; treatments with DHA or DXA produced an
excretion 3-fold (𝑃 < 0.01) higher than that of animals
receiving only the antifungal. When Gris was administrated
simultaneously with CHENO or URSO, PROTO IX levels in
feces were similar to their respective controls (Table 1).
3.4. Oxidative Stress. MDA levels were not changed in control
animals receiving only the bile acid assayed. Gris alone
or with DHA increased 80% (𝑃 < 0.01) MDA levels
(Figure 4(a)). Whereas URSO dropped 40% (𝑃 < 0.05) the
increase of MDA levels produced by Gris, the treatment with
CHENO or DXA returned MDA content to basal levels (𝑃 <
0.01) (Figure 4(a)).
The administration of URSO alone produced a 40%
(𝑃 < 0.01) enhancement of GSH levels, alike in mice
treated with Gris or with the combination of CHENO–Gris
or URSO–Gris. DXA and DHA restored GSH to basal levels
(Figure 4(b)).
None of the bile acids assayed modified the activity of
GRed in control animals. Gris induced 45% (𝑃 < 0.01)
GRed activity.These enhanced levels were not reversed by the
administration of CHENO, DHA, or DXA; however addition
of URSO decreased to 20% (𝑃 < 0.01) GRed activity induced
by Gris alone (Figure 4(c)).
The administration of DXA to control animals reduced
20% (𝑃 < 0.01) SOD activity, while no changes were pro-
duced by the other bile acids assayed. Gris induced 70% (𝑃 <
0.01) SOD activity. When animals received DXA or URSO
with Gris, this enzyme activity decreased 70% (𝑃 < 0.01) and
50% (𝑃 < 0.01), with respect to Gris group, reaching control
values (Figure 4(d)).
3.5. Drug Metabolizing System. CHENO administered to
control animals increased 25% (𝑃 < 0.01) GST activity,
without any alteration by the action of the other bile acids
studied. Gris induced 30% (𝑃 < 0.01) enzyme activity,
remaining enhanced after CHENOplusGris treatment. DHA
produced an additional induction (60% 𝑃 < 0.01) to that
induced by Gris. Instead, when DXA or URSO was given to
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1: Effect of bile acids on liver histology and HO1 immunostaining. (a) Gris (0.5% w/w) histology showing: liver plates disrupted
and distorted; hepatocellular degeneration with small foci of necrosis (circles); ductular proliferation; portal chronic infiltrate (arrows) and
cytoplasmic and canalicular cholestasis. HO1 immunostaining: (b) Gris (0.5% w/w) (arrows); (c) Gris (0.5% w/w) plus DHA (0.33% w/v)
(arrows); (d) Gris (0.5% w/w) plus CHENO (0.01% w/w) (arrows); (e) Gris (0.5% w/w) plus DXA (0.33% w/w) positive isolated hepatocytes
and Kupffer’s cells (arrows); (f) Gris (0.5%w/w) plus URSO (0.2%w/w) positive peri centrilobular vein hepatocytes (circle) and Kupffer’s cells
(arrows); (g) control; (h) control HO1 immunostaining. A unique photo of controls was shown because there were no differences between
this group and the groups only treated with the bile acids. Experimental details are described in Section 2.
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Figure 2: Effect of bile acids on liver/body weight ratio and on enzymesmarker of cholestasis. (a) Liver and body weight ratio; (b) GGT,mean
control value: 38.97± 5.0 𝜇U/mL (𝑛 = 6); (c) APmean control value: 421.5± 59.7mU/mL (𝑛 = 6).Mice received standard diet containing Gris
(0.5%, w/w), DHA (0.33% w/w), CHENO (0.01% w/w), DXA (0.33% w/w), URSO (0.20% w/w), or Gris plus one of the bile acids indicated
before, during 14 days. Control group received only standard diet in oil (vehicle used for solubilising Gris). Data represent mean values ± S.D.
of 6 mice. Results in Figure (b) and (c) are expressed as percentage of the corresponding control value taken as 100%. (∗∗)𝑃 < 0.01 significance
of differences between groups treated and the control group. (†)𝑃 < 0.05 and (††)𝑃 < 0.01, significance of differences between the group treated
with Gris plus bile acid with respect to the group receiving only bile acid. (+)𝑃 < 0.05 and (++)𝑃 < 0.01, significance of differences between the
group treated with Gris plus bile acid with respect to the group that received only Gris. Other experimental details are described in Section 2.
Gris feeding mice, GST activity returned to control values
(Figure 5(a)).
DHA and URSO administration to controls animals pro-
duced a 40% (𝑃 < 0.01) decrease of CYP levels, while no
changes after DXA or CHENO treatments were observed.
Gris leads to an increase of 40% (𝑃 < 0.01) in hepatic
CYP levels, without any modification when Gris was given
simultaneously with CHENO or ADX. DHA diminished
130% (𝑃 < 0.01) the hepatic CYP induction produced byGris.
Only URSO was able to reverse CYP levels to normal values
when it was given concomitantly with Gris (Figure 5(b)).
4. Discussion
In EPP patients, when hepatocellular damage progresses
to a critical stage, PROTO IX accumulation is markedly
accelerated due to biliary excretion impairment [30]. EPP
patients used bile acids to increase porphyrins excretion and
6 BioMed Research International
Table 1: Effect of bile acids on PROTO IX levels in liver and feces.
Bile acid
PROTO IX levels
Liver (ng/mg protein) Feces (ng/mg feces)
Without Gris With Gris Without Gris With Gris
NBA 0.42 ± 0.04 20.25 ± 3.58∗∗ 2.22 ± 0.04 10.25 ± 0.42∗∗
DHA 0.47 ± 0.07 2.88 ± 0.68++†† 3.88 ± 0.06 32.12 ± 0.57++††
CHENO 0.44 ± 0.06 20.94 ± 2.11∗∗†† 6.58 ± 0.008 6.85 ± 0.06
DXA 0.43 ± 0.09 1.11 ± 0.20++†† 2.53 ± 0.004 31.82 ± 0.38++††
URSO 0.51 ± 0.07 27.59 ± 3.58∗∗†† 02.07 ± 0.05 4.55 ± 0.05∗∗††
NBA: no bile acid added.
Mice received standard diet containing Gris (0.5%, w/w), DHA (0.33% w/w), CHENO (0.01% w/w), DXA (0.33% w/w), URSO (0.20% w/w), or Gris plus one
of the bile acids, over 14 days. Control group received only standard diet in oil (vehicle used for solubilising Gris). Data represent mean values ± S.D. of 6 mice.
∗∗
𝑃 < 0.01: significant difference between the groups treated with respect to the control group. ++𝑃 < 0.01 significance of differences between the group
treated with Gris plus bile acid with respect to the group that received only Gris. ††𝑃 < 0.01: significant difference between the group treated with Gris plus
bile acid with respect to the group treated only with bile acid. Other experimental details are described in Section 2.
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Figure 3: Effect of bile acids onALA-S activity. Results are expressed
as percentage of the corresponding control value taken as 100%.
ALA-S activity mean control value: 0.131 ± 0.019 nmol/mg protein
(𝑛 − 6). (∗∗)𝑃 < 0.01 significance of differences between groups
treated and control group. (++)𝑃 < 0.01 significance of differences
between the groups treated with Gris plus bile acid with respect
to the group receiving only Gris. More experimental details are
described in legend of Figure 2.
to improve cholestasis [11, 30, 31]. In liver perfusion studies,
Avner and Berenson [32] have observed that the limited
PROTO IX secretion into bile can be increased by bile salts,
supporting the hypothesis that the choleretic bile salts may
also increase PROTO IX secretion in protoporphyria.
In animal studies, published results are contradictory; in
mice treated with Gris, it was reported that URSO admin-
istration may have a cytoprotective and choleretic action on
the liver injury induced by Gris [33, 34] although Irifune et al.
[35] did not notice any effect after administration of URSO in
the same animal model.
In our model, the administration of different bile acids
led to several effects. Among the bile acids assayed, only DXA
andDHA increasedPROTOIX excretion.Wehave found that
URSO did not prevent porphyrins accumulation; however it
decreased ALA-S activity, indicating that it is acting on heme
biosynthesis. HO1 expression was induced as a consequence
of the oxidative stress produced by Gris and PROTO IX
accumulation; but this effect was not reversed after bile acids
treatment. In our study only URSO and DXA were able
to prevent enhancement of GGT and PA induced by Gris,
indicating the existence of certain protection against these
disturbances, althoughnohistological changeswere observed
when compared to the group treated only with Gris.
It has been reported that URSO possesses antioxidant
properties, while hydrophobic bile acids generate ROS acting
as prooxidants [36, 37]. Porphyrins produce ROS and thereby
an imbalance in the cell redox status. As expected, in animals
treated with DXA and Gris, an increase in PROTO IX
clearance leading to a decrease of lipid peroxidation was
detected, but this actionwas not observedwhen the other bile
acids were given. GSH levels remained within control values
when DHA and DXA were administered along with Gris.
Nevertheless these findings did not reflect the high activity of
GRed observed in the animals. However, URSO reduced the
induction of GRed without altering GSH levels. In previous
studies we have observed that GPx activity significantly
decreased in mice treated with Gris, so we might assume
that other enzymes were consuming GSH [17]. SOD activity
remained within control values in mice treated with URSO,
DXA alone or plus Gris.
The increase of GST activity in mice receiving Gris is
indicative of liver damage [15]. It has been described that,
under oxidative stress, GST is activated by the generation of S-
thiolation mediated by hydroperoxides, with GSH being the
donor of the SH groups in a reversible reaction, that depends
on the intracellular GSH redox balance [38]. So the increase
of GST activity observed in our model would be related to
the levels of hepatic GSH and ROS [17]. In the presence
of cholestasis, Phase I drug metabolizing system plays an
important role in both humans [39] and animal models [40,
41]. Tanaka et al. [42] suggested that the decreasedCYP levels,
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Figure 4: Effect of bile acid on MDA, GSH levels and liver antioxidant defense system. (a) MDA levels, mean control value: 7.94 ±
1.39 nmol/mg protein (𝑛 − 6). (b) GSH levels, mean control value: 27.05 ± 5.11 nmol/mg protein (𝑛 − 6). (c) GRed, mean control value: 40.11
± 4.96 nmol/mg protein (𝑛 − 4); (d) SOD, mean control value: 71.95 ± 10.93 nmol/mg protein (𝑛 − 6). Results are expressed as percentage of
the corresponding control value taken as 100%. (∗)𝑃 < 0.05 and (∗∗)𝑃 < 0.01, significance of differences between the groups treated and the
control group. (+)𝑃 < 0.05 and (++)𝑃 < 0.01, significance of differences between the group treated with Gris plus bile acid with respect to that
receiving only Gris. (†)𝑃 < 0.05 and (††)𝑃 < 0.01, significance of differences between the group treated with Gris plus bile acid with respect to
the group receiving only bile acid. More experimental details are described in legend of Figure 2.
after treatment with DXA, could occur due to the presence
of cholestasis and could also reflect the toxicity of these bile
acids.
We have previously observed an increase of hepatic CYP
levels in animals treated with Gris alone [17], but it did not
happenwhenmicewere simultaneously treatedwithGris and
DHA,DXA, orURSO, indicating that these drugs would alter
Gris metabolism.
In conclusion, taking into account that DXA effectively
reduced porphyrins accumulation induced by Gris and con-
sequently protected the liver against lipid peroxidation and
maintaining GSH levels, GGT and AP activities, and drug
metabolizing system in basal levels, we postulate that this
bile acid would be the most effective in preventing the liver
damage induced by Gris.
Abbreviations
ALA-S: 𝛿-Aminolevulinic acid synthetase
AP: Alkaline phosphatase
CHENO: Chenodeoxycholic acid
CYP: Cytochrome P450
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Figure 5: Effect of bile acids on GST activity and on CYP levels. (a) GST, mean control value: 22.77 ± 1.20𝜇nmol/mg protein (𝑛 − 6); (b)
CYP levels. Results in (a) are expressed as percentage of the corresponding control value taken as 100%; in (b) data are expressed as mean
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significance of differences between the groups treated with Gris plus bile acid with respect to the group receiving only Gris. (†)𝑃 < 0.05 and
(††)
𝑃 < 0.01, significance of differences between the group treated with Gris plus bile acid with respect to the group receiving only bile acid.
More experimental details are described in legend of Figure 2.
DHA: Dehydrocholic acid
DXA: Deoxycholic acid
EPP: Erythropoietic protoporphyria
Fech: Ferrochelatase
GGT: Gamma glutamyl transpeptidase
GPx: Glutathione peroxidase
GRed: Glutathione reductase
Gris: Griseofulvin
GSH: Reduced glutathione
GST: Glutathione-S-transferase
HO1: Heme oxygenase
MDA: Malondialdehyde
ROS: Reactive oxygen species
PROTO IX: Protoporphyrin IX
S.D.: Standard deviation
SOD: Superoxide dismutase
URSO: Ursodeoxycholic acid.
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